Thank you Madrigal for your support on this Medication Review Video Module.

Dr. Reed Hogan, a practicing gastroenterologist in Jackson, Mississippi, shares his clinical experience and insights on Resmetirom, the first FDA-approved therapy for MASH (Metabolic Dysfunction-Associated Steatohepatitis). With over 6,000 patients screened annually in his metabolic and fatty liver clinics, Dr. Hogan highlights the urgent need for effective treatment options in fibrotic liver disease and how Resmetirom is filling that gap. He explains the drug’s novel mechanism of action as a thyroid hormone receptor beta (THR-β) agonist, its ability to reduce triglycerides within liver cells, and its impact on reducing inflammation and fibrosis. Drawing from real-world experience with over 100 patients on therapy, Dr. Hogan discusses the favorable safety profile—primarily mild and self-limited GI side effects—and emphasizes why every liver care provider should be considering Resmetirom as a frontline option beyond lifestyle interventions. Tune in for a practical, expert-led update on one of the most significant advancements in liver disease management in decades.